Novel transdermal vaccine delivery

新型透皮疫苗递送

• 批准号: 183530
• 负责人: Dutz Jan P
• 金额: $ 6.89万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2009
• 资助国家: 加拿大
• 起止时间: 2009-03-01 至 2010-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=183530&lang=en
• 关键词: Adjuvant; Dendritic Cell; Microneedle; Skin; T Cell; Vaccination

Current vaccine technologies are inadequate to counter the threat posed by existing and emerging infectious agents. This is due in part to the limited ability of current vaccines to induce effective cellular immune responses, the short duration of immune

目前的疫苗技术不足以应对现有和新出现的传染病病原体构成的威胁。这在一定程度上是由于目前疫苗诱导有效细胞免疫反应的能力有限，免疫持续时间较短。